Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 3.5% – Should You Sell?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded down 3.5% during mid-day trading on Tuesday . The stock traded as low as $19.82 and last traded at $19.64. 537,413 shares changed hands during trading, a decline of 40% from the average session volume of 896,224 shares. The stock had previously closed at $20.35.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Morgan Stanley cut their price objective on Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. UBS Group dropped their price target on Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Canaccord Genuity Group assumed coverage on Celldex Therapeutics in a research report on Monday, April 28th. They set a “buy” rating and a $64.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $53.90.

Celldex Therapeutics Trading Down 2.5%

The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -7.73 and a beta of 1.39. The firm has a 50-day moving average of $18.92 and a 200 day moving average of $22.31.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. Equities research analysts predict that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares in the last quarter. Invesco Ltd. boosted its stake in Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company’s stock valued at $1,064,000 after purchasing an additional 871 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 878 shares in the last quarter. Values First Advisors Inc. boosted its stake in Celldex Therapeutics by 3.2% during the 1st quarter. Values First Advisors Inc. now owns 29,933 shares of the biopharmaceutical company’s stock valued at $550,000 after purchasing an additional 924 shares in the last quarter. Finally, Swiss National Bank boosted its stake in Celldex Therapeutics by 1.2% during the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock valued at $2,964,000 after purchasing an additional 1,400 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.